The report analyzes and forecasts the prostate cancer therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of prostate cancer therapeutics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major prostate cancer therapeutics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of prostate cancer therapeutics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of prostate cancer therapeutics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global prostate cancer therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the prostate cancer therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of prostate cancer therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Some of the major players include, but are not limited to, Johnson & Johnson; Astella, Inc.; Sanofi; Ipsen; Bayer AG; AstraZeneca; and Valeant Pharmaceuticals North America LLC (Dendreon Corporation). These major players dominate the market due to their strong brand identity coupled with a wide geographic reach.
Report Segmentation:
Drugs Outlook
Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
Zytiga
Gonax
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Lupron
Zoladex
Eligard
Decapeptyl
Vantas
Others
Anti-Androgen
Xtandi
Casodex
Chemotherapy
Taxotere
Jevtana
Immunotherapy
Provenge
Targeted Therapy
Xofigo
Regional Outlook
North America
U.S.
Canada
Europe
Germany
UK
Asia Pacific
China
Japan
Latin America
Mexico
Brazil
MEA
South Africa
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
Chapter 2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
Chapter 3. Executive Summary
3.1. Global Prostate Cancer Therapeutics Market : Snapshot
3.2. Global Prostate Cancer Therapeutics Market : Opportunity Map
Chapter 4. Market Overview
4.1. Product Overview
4.2. Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, 2017–2026
4.3. Global Prostate Cancer Therapeutics Market Outlook
4.4. Global Prostate Cancer Therapeutics Market : Key Industry Events
4.5. Global Prostate Cancer Therapeutics Market : Porter's Analysis
4.6. Global Prostate Cancer Therapeutics Market : Pipeline Analysis
4.7. Key Product Opportunities
Chapter 5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Increasing prevalence of prostate cancer
5.2.2. Launch of promising emerging therapies
5.2.3. Innovation in the development of new drugs and therapeutic biological products
5.2.4. High growth in hormone-refractory prostate cancer drug due to lesser side effects
5.3. Restrains
5.3.1. High cost of treatment
5.3.2. Reluctance toward adoption of premium treatments
5.4. Opportunity Analysis
5.5. Opportunities
5.5.1. Large undiagnosed patient population
5.5.2. Rise in funding from both public and private sector in the field of drug development
5.6. Key Trends
5.6.1. Increasing application of biotechnology in anticancer drugs development
5.6.2. New drugs entering the market with higher costs
5.6.3. Oral drugs account for a large share of the oncology drugs market
Chapter 6. Prostate Cancer Therapeutics Market Analysis, by Product Type
6.1. Prostate Cancer Therapeutics Market Analysis, by Therapy
6.2. Key Findings
6.3. Introduction
6.4. Global Prostate Cancer Therapeutics Market Value Share Analysis, by Therapy
6.5. Prostate Cancer Therapeutics Market Analysis, by Therapy
6.5.1. Hormone Therapy
6.5.2. Luteinizing Hormone-Releasing Hormone Analogs
6.5.3. Luteinizing Hormone-Releasing Hormone Antagonists
6.5.4. Antiandrogens
6.6. Chemotherapy
6.6.1. Systemic Chemotherapy
6.6.2. Regional Chemotherapy
6.7. Biologic Therapy
6.8. Targeted Therapy
6.9. Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2019-2026
6.10. Key Trends
Chapter 7. Prostate Cancer Therapeutics Market Analysis, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.3. Global Prostate Cancer Therapeutics Market Value Share Analysis, by Distribution Channel
7.4. Prostate Cancer Therapeutics Market Analysis, by Distribution Channel
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Sales
7.4.4. Others
7.5. Market Attractiveness Analysis, by Distribution Channel
7.6. Key Trends
Chapter 8. Prostate Cancer Therapeutics Market Analysis, by Region
8.1. Global Prostate Cancer Therapeutics Market Snapshot, by Country
8.2. Global Prostate Cancer Therapeutics Market Value Share Analysis, by Region
8.3. Prostate Cancer Therapeutics Market Forecast, by Region
8.4. Prostate Cancer Therapeutics Market Attractiveness Analysis, by Region, 2019-2026
Chapter 9. North America Prostate Cancer Therapeutics Market Analysis
9.1. Key Findings
9.2. North America Prostate Cancer Therapeutics Market Overview
9.3. North America Market Value Share Analysis, by Therapy
9.4. North America Market Forecast, by Therapy
9.4.1. Hormone Therapy
9.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
9.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
9.4.1.3. Antiandrogens
9.4.2. Chemotherapy
9.4.2.1. Systemic Chemotherapy
9.4.2.2. Regional Chemotherapy
9.4.3. Biologic Therapy
9.4.4. Targeted Therapy
9.5. North America Market Value Share Analysis, by Distribution Channel
9.6. North America Market Forecast, by Distribution Channel
9.6.1. Hospital Pharmacy
9.6.2. Retail Pharmacy
9.6.3. Online Sales
9.6.4. Others
9.7. Market Analysis, by Country
9.8. Market Value Share Analysis, by Country
9.9. Market Size (US$ Mn) Forecast, by Country, 2019–2026
9.9.1. U.S.
9.9.2. Canada
9.10. Market Attractiveness Analysis
9.10.1. By Product
9.10.2. By Distribution Channel
9.10.3. By Country
9.11. Market Trends
Chapter 10. Europe Prostate Cancer Therapeutics Market Analysis
10.1. Key Findings
10.2. Europe Prostate Cancer Therapeutics Market Overview
10.3. Europe Market Value Share Analysis, by Therapy
10.4. Europe Market Forecast, by Therapy
10.4.1. Hormone Therapy
10.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
10.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
10.4.1.3. Antiandrogens
10.4.2. Chemotherapy
10.4.2.1. Systemic Chemotherapy
10.4.2.2. Regional Chemotherapy
10.4.3. Biologic Therapy
10.4.4. Targeted Therapy
10.5. Europe Market Value Share Analysis, by Distribution Channel
10.6. Europe Market Forecast, by Distribution Channel
10.6.1. Hospital Pharmacy
10.6.2. Retail Pharmacy
10.6.3. Online Sales
10.6.4. Others
10.7. Market Analysis, by Country
10.8. Market Value Share Analysis, by Country
10.9. Market Size (US$ Mn) Forecast, by Country, 2019–2026
10.9.1. U.K.
10.9.2. Germany
10.9.3. Italy
10.9.4. France
10.9.5. Spain
10.9.6. Russia
10.9.7. Rest of Europe
10.10. Market Attractiveness Analysis
10.10.1. By Product
10.10.2. By Distribution Channel
10.10.3. By Country
10.11. Market Trends
Chapter 11. Asia Pacific Prostate Cancer Therapeutics Market Analysis
11.1. Key Findings
11.2. Asia Pacific Prostate Cancer Therapeutics Market Overview
11.3. Asia Pacific Market Value Share Analysis, by Therapy
11.4. Asia Pacific Market Forecast, by Therapy
11.4.1. Hormone Therapy
11.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
11.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
11.4.1.3. Antiandrogens
11.4.2. Chemotherapy
11.4.2.1. Systemic Chemotherapy
11.4.2.2. Regional Chemotherapy
11.4.3. Biologic Therapy
11.4.4. Targeted Therapy
11.5. Asia Pacific Market Value Share Analysis, by Distribution Channel
11.6. Asia Pacific Market Forecast, by Distribution Channel
11.6.1. Hospital Pharmacy
11.6.2. Retail Pharmacy
11.6.3. Online Sales
11.6.4. Others
11.7. Market Analysis, by Country
11.8. Market Value Share Analysis, by Country
11.9. Market Size (US$ Mn) Forecast, by Country, 2019–2026
11.9.1. China
11.9.2. Japan
11.9.3. India
11.9.4. Australia & New Zealand
11.9.5. Rest of Asia Pacific
11.10. Market Attractiveness Analysis
11.10.1. By Product
11.10.2. By Distribution Channel
11.10.3. By Country
11.11. Market Trends
Chapter 12. Latin America Prostate Cancer Therapeutics Market Analysis
12.1. Key Findings
12.2. Latin America Prostate Cancer Therapeutics Market Overview
12.3. Latin America Market Value Share Analysis, by Therapy
12.4. Latin America Market Forecast, by Therapy
12.4.1. Hormone Therapy
12.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
12.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
12.4.1.3. Antiandrogens
12.4.2. Chemotherapy
12.4.2.1. Systemic Chemotherapy
12.4.2.2. Regional Chemotherapy
12.4.3. Biologic Therapy
12.4.4. Targeted Therapy
12.5. Latin America Market Value Share Analysis, by Distribution Channel
12.6. Latin America Market Forecast, by Distribution Channel
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Sales
12.6.4. Others
12.7. Market Analysis, by Country
12.8. Market Value Share Analysis, by Country
12.9. Market Size (US$ Mn) Forecast, by Country, 2019–2026
12.9.1. Brazil
12.9.2. Mexico
12.9.3. Rest of Latin America
12.10. Market Attractiveness Analysis
12.10.1. By Product
12.10.2. By Distribution Channel
12.10.3. By Country
12.11. Market Trends
Chapter 13. Middle East & Africa Prostate Cancer Therapeutics Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Prostate Cancer Therapeutics Market Overview
13.3. Middle East & Africa Market Value Share Analysis, by Therapy
13.4. Middle East & Africa Market Forecast, by Therapy
13.4.1. Hormone Therapy
13.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
13.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
13.4.1.3. Antiandrogens
13.4.2. Chemotherapy
13.4.2.1. Systemic Chemotherapy
13.4.2.2. Regional Chemotherapy
13.4.3. Biologic Therapy
13.4.4. Targeted Therapy
13.5. Middle East & Africa Market Value Share Analysis, by Distribution Channel
13.6. Middle East & Africa Market Forecast, by Distribution Channel
13.6.1. Hospital Pharmacy
13.6.2. Retail Pharmacy
13.6.3. Online Sales
13.6.4. Others
13.7. Market Analysis, by Country
13.8. Market Value Share Analysis, by Country
13.9. Market Size (US$ Mn) Forecast, by Country, 2019–2026
13.9.1. Brazil
13.9.2. Mexico
13.9.3. Rest of Latin America
13.10. Market Attractiveness Analysis
13.10.1. By Product
13.10.2. By Distribution Channel
13.10.3. By Country
13.11. Market Trends
Chapter 14. Company Profiles
14.1. Prostate Cancer Therapeutics Market Share Analysis, by Company, 2019 (Estimated)
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. Amgen, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Johnson & Johnson (Janssen Biotech, Inc.)
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. AstraZeneca
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. AbbVie, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Bayer AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Ipsen Group
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Sanofi
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Endo Pharmaceuticals, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Dendreon Corporation (Sanpower Group Co. Ltd.)
14.3.10.1. Company Overview (HQ, Business Segments,)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers